Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
Journal
Headache
ISSN: 1526-4610
Titre abrégé: Headache
Pays: United States
ID NLM: 2985091R
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
accepted:
15
08
2019
entrez:
19
9
2019
pubmed:
19
9
2019
medline:
14
7
2020
Statut:
ppublish
Résumé
To provide evidence-based recommendations for the acute symptomatic treatment of children and adolescents with migraine. We performed a systematic review of the literature and rated risk of bias of included studies according to the American Academy of Neurology classification of evidence criteria. A multidisciplinary panel developed practice recommendations, integrating findings from the systematic review and following an Institute of Medicine-compliant process to ensure transparency and patient engagement. Recommendations were supported by structured rationales, integrating evidence from the systematic review, related evidence, principles of care, and inferences from evidence. There is evidence to support the efficacy of the use of ibuprofen, acetaminophen (in children and adolescents), and triptans (mainly in adolescents) for the relief of migraine pain, although confidence in the evidence varies between agents. There is high confidence that adolescents receiving oral sumatriptan/naproxen and zolmitriptan nasal spray are more likely to be headache free at 2 hours than those receiving placebo. No acute treatments were effective for migraine-related nausea or vomiting; some triptans were effective for migraine-related phonophobia and photophobia. Recommendations for the treatment of acute migraine in children and adolescents focus on the importance of early treatment, choosing the route of administration best suited to the characteristics of the individual migraine attack, and providing counselling on lifestyle factors that can exacerbate migraine, including trigger avoidance and medication overuse.
Substances chimiques
Analgesics
0
Types de publication
Journal Article
Practice Guideline
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1158-1173Informations de copyright
© 2019 American Headache Society.
Références
Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629-808.
Neurology AAo. Clinical Practice Guideline Process Manual, 2011 ed. St. Paul, MN: The American Academy of Neurology; 2011.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926.
Winner P, Rothner AD, Wooten JD, Webster C, Ames M. Sumatriptan nasal spray in adolescent migraineurs: A randomized, double-blind, placebo-controlled, acute study. Headache. 2006;46:212-222.
Fujita M, Sato K, Nishioka H, Sakai F. Oral sumatriptan for migraine in children and adolescents: A randomized, multicenter, placebo-controlled, parallel group study. Cephalalgia. 2014;34:365-375.
Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics. 2000;106:989-997.
Ahonen K, Hamalainen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial. Neurology. 2004;62:883-887.
Lewis DW, Winner P, Hershey AD, Wasiewski WW, Adolescent Migraine Steering Committee. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics. 2007;120:390-396.
Visser WH, Winner P, Strohmaier K, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: Results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache. 2004;44:891-899.
Ho TW, Pearlman E, Lewis D, et al. Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia. 2012;32:750-765.
Winner P, Lewis D, Visser WH, Jiang K, Ahrens S, Evans JK. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: A randomized double-blind, placebo-controlled study. Headache. 2002;42:49-55.
Hamalainen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: A double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997;48:103-107.
Lewis DW, Kellstein D, Dahl G, et al. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache. 2002;42:780-786.
Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW. Efficacy and tolerability of almotriptan in adolescents: A randomized, double-blind, placebo-controlled trial. Headache. 2008;48:1326-1336.
Winner P, Farkas V, Stillova H, et al. Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ). Headache. 2016;56:1107-1119.
Winner P, Linder SL, Lipton RB, Almas M, Parsons B, Pitman V. Eletriptan for the acute treatment of migraine in adolescents: Results of a double-blind, placebo-controlled trial. Headache. 2007;47:511-518.
Derosier FJ, Lewis D, Hershey AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics. 2012;129:e1411-e1420.
Winner P, Linder S, Hershey AD. Consistency of response to sumatriptan/naproxen sodium in a randomized placebo-controlled, cross-over study for the acute treatment of migraine in adolescence. Headache. 2015;55:519-528.
Hershey AD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol. 2010;9:190-204.
Lanteri-Minet M, Mick G, Allaf B. Early dosing and efficacy of triptans in acute migraine treatment: The TEMPO study. Cephalalgia. 2012;32:226-235.
Bigal ME, Lipton RB, Winner P, et al. Migraine in adolescents: Association with socioeconomic status and family history. Neurology. 2007;69:16-25.
Farkkila M, Olesen J, Dahlof C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003;23:463-471.
Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: Effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994;14:330-338.
Buse DC, Loder EW, Gorman JA, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53:1278-1299.
Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci. 1998;6:99-104.
Uemura N, Onishi T, Mitaniyama A, et al. Bioequivalence and rapid absorption of zolmitriptan nasal spray compared with oral tablets in healthy Japanese subjects. Clin Drug Invest. 2005;25:199-208.
Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia. 1998;18:532-538.
Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, double-blind, placebo-controlled, dose ranging study versus zolmitriptan tablet. CNS Drugs. 2003;17:653-667.
Haberer LJ, Walls CM, Lener SE, Taylor DR, McDonald SA. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2010;50:357-373.
Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA. 2007;297:1443-1454.
Fedorowicz Z, Jagannath VA, Carter B. Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev. 2011:CD005506.
Carter B, Fedorowicz Z. Antiemetic treatment for acute gastroenteritis in children: An updated Cochrane systematic review with meta-analysis and mixed treatment comparison in a Bayesian framework. BMJ Open. 2012;2:e000622.
Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008;48:1157-1168.
Dodick D, Lipton RB, Martin V, et al. Consensus statement: Cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache. 2004;44:414-425.
Humphrey PP, Feniuk W, Perren MJ, Connor HE, Oxford AW. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia. 1989;9(Suppl. 9):23-33.
Carel I, Ghaleh B, Edouard A, et al. Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs. Br J Pharmacol. 2001;132:1071-1083.
Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology. 1994;44:1587-1592.
Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol. 2004;11:671-677.
Evers S, Marziniak M, Frese A, Gralow I. Placebo efficacy in childhood and adolescence migraine: An analysis of double-blind and placebo-controlled studies. Cephalalgia. 2009;29:436-444.
Kabbouche M. Management of pediatric migraine headache in the emergency room and infusion center. Headache. 2015;55:1365-1370.
Kabbouche MA, Vockell AL, LeCates SL, Powers SW, Hershey AD. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics. 2001;107:E62.
Richer LP, Laycock K, Millar K, et al. Treatment of children with migraine in emergency departments: National practice variation study. Pediatrics. 2010;126:e150-e155.